Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

English version České info

Background:
Sevelamer is an alternative to calcium carbonate for the treatment of hyperphosphatemia among non-dialysis dependent patients with chronic kidney disease (CKD). Although some studies show that it may reduce mortality and delay the onset of dialysis when compared to calcium carbonate, it is also significantly more expensive. Prior studies looking at the incremental cost-effectiveness of sevelamer versus calcium carbonate in pre-dialysis patients are based on data from a single clinical trial. The goal of our study is to use a wider range of clinical data to achieve a more contemporary and robust cost-effectiveness analysis.

Methods:
We used a Markov model to estimate the lifetime costs and quality-adjusted life years (QALYs) gained for treatment with sevelamer versus calcium carbonate. The model simulated transitions among three health states (CKD not requiring dialysis, end-stage renal disease, and death). Data on transition probabilities and utilities were obtained from the published literature. Costs were calculated from a third party payer perspective and included medication, hospitalization, and dialysis. Sensitivity analyses were also run to encompass a wide range of assumptions about the dose, costs, and effectiveness of sevelamer.

Results:
Over a lifetime, the average cost per patient treated with sevelamer is S0,724. The estimated cost for patients treated with calcium carbonate is S2,988. A patient treated with sevelamer gains, on average, 6.34 QALYs relative to no treatment, whereas a patient taking calcium carbonate gains 5.81 QALYs. Therefore, sevelamer produces an incremental cost-effectiveness ratio (ICER) of S,756 per QALY gained relative to calcium carbonate.

Conclusion:
Based on established benchmarks for cost-effectiveness, sevelamer is cost effective relative to calcium carbonate for the treatment of hyperphosphatemia among patients with chronic kidney disease initially not on dialysis.

Keywords:
Sevelamer, Calcium carbonate, Dialysis, Hyperphosphatemia, Chronic kidney disease, Cost-effectiveness

Autoři: Hai V. Nguyen ^1*; Saideep Bose ²; Eric Finkelstein ¹
Působiště autorů: Program in Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore. ¹; Division of Cardiac, Thoracic, and Vascular Surgery, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. ²
Vyšlo v časopise: BMC Nefrol 2016, 17:45
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1186/s12882-016-0256-0

© Nguyen et al. 2016
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: http://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-016-0256-0

Souhrn

Keywords:
Sevelamer, Calcium carbonate, Dialysis, Hyperphosphatemia, Chronic kidney disease, Cost-effectiveness

Zdroje

1. National Registry of Diseases Office, MOH. Singapore. Singapore Renal Registry Annual Registry Report 1999–2013 (Preliminary). 2014. p. 1–19.

2. NKF KDOQI GUIDELINES. 2003. https://www.kidney.org/sites/default/files/docs/boneguidelines.pdf. Accessed 24 April 2016.

3. Benot AR. Mild hyperphosphatemia and mortality in haemodialysis patients. Am J Kidney Dis. 2005;46:68–77.

4. Block GA et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;8:2208–18.

5. Navaneethan SD. Benefits and harms of phosphate binders in CKD: a systemic review of randomized controlled trials. Am J Kidney Dis. 2009;54(4):610–37.

6. Di Iorio B, Bellasi A, Russo D, on behalf of the Independent Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487–93.

7. Jamal Sophie A, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–77.

8. Melissa T, Bartko-Winters S, Bernard L, et al. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ; 2014. 2013;16(6):744–55.

9. Ruggeri M. Sevelamer is cost-effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. J Nephrol. 2014.28(5):593–602.

10. Di Iorio B, Bellasi A, Russo D, on behalf of the Independent Study Investigators. Correction to mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3): 487–93.

11. Department of Statistics, Singapore. Complete Life Tables 2008–2013 for Singapore Resident Population. 2014. Available at: http://www.singstat.gov.sg/docs/default-source/default-document-library/publications/publications_and_papers/births_and_deaths/lifetable08-13.pdf. Accessed 24 April 2016.

12. Pang WC, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–82.

13. United States Renal Data System. 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.

14. Wong JS, Port FK, Hulbert-Shearon TE, Carroll CE, Wolfe RA, Agodoa LY, Daugirdas JT. Survival advantage in Asian American end-stage renal disease patients. Kidney Int. 1999;55(6):2515–23.

15. Keith MS. Cost-minimization analysis of lanthum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease. Clin Ther. 2014; 36:1276–86.

16. Ministry of Health, Singapore. Hospital Bill Sizes for Admission for Kidney failure, vol. 1. 2014. Available at: https://www.moh.gov.sg/content/moh_web/home/costs_and_financing/hospital-charges/Total-Hospital-Bills-Bycondition-procedure/kidney_failure.html. Accessed 24 April 2016.

17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

18. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229–36.

19. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445–54.

20. Gorodetskaya I, Zenios S, Mcculloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–8.

21. NICE. Guide to the methods of technology appraisal. UK: NICE; 2013.

22. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006.

23. D’Haese PC et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003;63:S73–8.